ArticleFrontiers in neurology2025
Global trends and future projections of migraine burden in children aged 5 to 14 from 1990 to 2050.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Disparities in Headache Care and Research in Children and Adolescents: A Narrative Review.Current pain and headache reports · 2026Review
- Simultaneous Use of Continuous Glucose Monitoring (CGM) Systems and the Remote Electrical Neuromodulation (REN) Wearable for Patients with Comorbid Diabetes and Migraine: An Interventional Single-Arm Compatibility Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a leading cause of disability, yet its burden in children aged 5 to 14 remains underexplored. Using Global Burden of Disease (GBD) 2021 data, we analyzed global, regional, and national migraine burdens from 1990 to 2021. Age-standardized incidence (ASIR), age-standardized prevalence (ASPR), and disability-adjusted life years (DALY) were assessed, with estimated annual percent change (EAPC) used for trend evaluation. A Bayesian Age-Period-Cohort (BAPC) model projected incidence to 2050. Globally, migraine cases rose by 39.5% (21.95 to 26.87 million), though ASIR, ASPR, and DALY rates remained stable. Low-middle Sociodemographic Index (SDI) regions had the highest prevalence (31.19 million) and DALY (1.11 million), while high SDI regions recorded the highest female incidence rates. Western Sub-Saharan Africa showed the largest increases across all metrics (EAPCs > 3.0). Brazil reported high ASIR and DALY, while Thailand had the greatest DALY reduction, likely due to effective public health measures. Projections suggest declining ASIR, ASPR, and DALY rates by 2050. These findings indicated absolute cases of migraine have increased due to population growth, the age-standardized burden has remained stable over time. Strengthened surveillance, targeted screening in low-middle SDI regions, and school-based awareness programs in high-burden countries are essential to mitigating migraine-related disability in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.